Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway

Cecilia Ratner, Zhenyan He, Kaare V. Grunddal, Louise J. Skov, Bolette Hartmann, Fa Zhang, Annette Feuchtinger, Anette Bjerregaard, Christina Christoffersen, Matthias H. Tschöp, Brian Finan, Richard D. DiMarchi, Gina M. Leinninger, Kevin W Williams, Christoffer Clemmensen, Birgitte Holst

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Neurotensin (NT), a gut hormone and neuropeptide, increases in circulation after bariatric surgery in rodents and humans and inhibits food intake in mice. However, its potential to treat obesity and the subsequent metabolic dysfunctions have been difficult to assess owing to its short half-life in vivo. Here, we demonstrate that a long-acting, pegylated analog of the NT peptide (P-NT) reduces food intake, body weight, and adiposity in diet-induced obese mice when administered once daily for 6 days. Strikingly, when P-NT was combined with the glucagon-like peptide 1 mimetic liraglutide, the two peptides syner-gized to reduce food intake and body weight relative to each monotherapy, without inducing a taste aversion. Further, P-NT and liraglutide coadministration improved glycemia and reduced steatohepatitis. Finally, we show that the melanocortin pathway is central for P-NT–induced anorexia and necessary for the full synergistic effect of P-NT and liraglutide combination therapy. Overall, our data suggest that P-NT and liraglutide combination therapy could be an enhanced treatment for obesity with improved tolerability compared with liraglutide monotherapy.

Original languageEnglish (US)
Pages (from-to)1329-1340
Number of pages12
JournalDiabetes
Volume68
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Melanocortins
Neurotensin
Obesity
Eating
Body Weight
Obese Mice
Glucagon-Like Peptide 1
Bariatric Surgery
Adiposity
Anorexia
Fatty Liver
Liraglutide
Neuropeptides
Half-Life
Rodentia
Therapeutics
Hormones
Diet
Peptides

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Ratner, C., He, Z., Grunddal, K. V., Skov, L. J., Hartmann, B., Zhang, F., ... Holst, B. (2019). Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway. Diabetes, 68(6), 1329-1340. https://doi.org/10.2337/db18-1009

Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway. / Ratner, Cecilia; He, Zhenyan; Grunddal, Kaare V.; Skov, Louise J.; Hartmann, Bolette; Zhang, Fa; Feuchtinger, Annette; Bjerregaard, Anette; Christoffersen, Christina; Tschöp, Matthias H.; Finan, Brian; DiMarchi, Richard D.; Leinninger, Gina M.; Williams, Kevin W; Clemmensen, Christoffer; Holst, Birgitte.

In: Diabetes, Vol. 68, No. 6, 01.06.2019, p. 1329-1340.

Research output: Contribution to journalArticle

Ratner, C, He, Z, Grunddal, KV, Skov, LJ, Hartmann, B, Zhang, F, Feuchtinger, A, Bjerregaard, A, Christoffersen, C, Tschöp, MH, Finan, B, DiMarchi, RD, Leinninger, GM, Williams, KW, Clemmensen, C & Holst, B 2019, 'Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway', Diabetes, vol. 68, no. 6, pp. 1329-1340. https://doi.org/10.2337/db18-1009
Ratner, Cecilia ; He, Zhenyan ; Grunddal, Kaare V. ; Skov, Louise J. ; Hartmann, Bolette ; Zhang, Fa ; Feuchtinger, Annette ; Bjerregaard, Anette ; Christoffersen, Christina ; Tschöp, Matthias H. ; Finan, Brian ; DiMarchi, Richard D. ; Leinninger, Gina M. ; Williams, Kevin W ; Clemmensen, Christoffer ; Holst, Birgitte. / Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway. In: Diabetes. 2019 ; Vol. 68, No. 6. pp. 1329-1340.
@article{9d0de89021494b4f9c136006c7898ec9,
title = "Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway",
abstract = "Neurotensin (NT), a gut hormone and neuropeptide, increases in circulation after bariatric surgery in rodents and humans and inhibits food intake in mice. However, its potential to treat obesity and the subsequent metabolic dysfunctions have been difficult to assess owing to its short half-life in vivo. Here, we demonstrate that a long-acting, pegylated analog of the NT peptide (P-NT) reduces food intake, body weight, and adiposity in diet-induced obese mice when administered once daily for 6 days. Strikingly, when P-NT was combined with the glucagon-like peptide 1 mimetic liraglutide, the two peptides syner-gized to reduce food intake and body weight relative to each monotherapy, without inducing a taste aversion. Further, P-NT and liraglutide coadministration improved glycemia and reduced steatohepatitis. Finally, we show that the melanocortin pathway is central for P-NT–induced anorexia and necessary for the full synergistic effect of P-NT and liraglutide combination therapy. Overall, our data suggest that P-NT and liraglutide combination therapy could be an enhanced treatment for obesity with improved tolerability compared with liraglutide monotherapy.",
author = "Cecilia Ratner and Zhenyan He and Grunddal, {Kaare V.} and Skov, {Louise J.} and Bolette Hartmann and Fa Zhang and Annette Feuchtinger and Anette Bjerregaard and Christina Christoffersen and Tsch{\"o}p, {Matthias H.} and Brian Finan and DiMarchi, {Richard D.} and Leinninger, {Gina M.} and Williams, {Kevin W} and Christoffer Clemmensen and Birgitte Holst",
year = "2019",
month = "6",
day = "1",
doi = "10.2337/db18-1009",
language = "English (US)",
volume = "68",
pages = "1329--1340",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "6",

}

TY - JOUR

T1 - Long-acting neurotensin synergizes with liraglutide to reverse obesity through a melanocortin-dependent pathway

AU - Ratner, Cecilia

AU - He, Zhenyan

AU - Grunddal, Kaare V.

AU - Skov, Louise J.

AU - Hartmann, Bolette

AU - Zhang, Fa

AU - Feuchtinger, Annette

AU - Bjerregaard, Anette

AU - Christoffersen, Christina

AU - Tschöp, Matthias H.

AU - Finan, Brian

AU - DiMarchi, Richard D.

AU - Leinninger, Gina M.

AU - Williams, Kevin W

AU - Clemmensen, Christoffer

AU - Holst, Birgitte

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Neurotensin (NT), a gut hormone and neuropeptide, increases in circulation after bariatric surgery in rodents and humans and inhibits food intake in mice. However, its potential to treat obesity and the subsequent metabolic dysfunctions have been difficult to assess owing to its short half-life in vivo. Here, we demonstrate that a long-acting, pegylated analog of the NT peptide (P-NT) reduces food intake, body weight, and adiposity in diet-induced obese mice when administered once daily for 6 days. Strikingly, when P-NT was combined with the glucagon-like peptide 1 mimetic liraglutide, the two peptides syner-gized to reduce food intake and body weight relative to each monotherapy, without inducing a taste aversion. Further, P-NT and liraglutide coadministration improved glycemia and reduced steatohepatitis. Finally, we show that the melanocortin pathway is central for P-NT–induced anorexia and necessary for the full synergistic effect of P-NT and liraglutide combination therapy. Overall, our data suggest that P-NT and liraglutide combination therapy could be an enhanced treatment for obesity with improved tolerability compared with liraglutide monotherapy.

AB - Neurotensin (NT), a gut hormone and neuropeptide, increases in circulation after bariatric surgery in rodents and humans and inhibits food intake in mice. However, its potential to treat obesity and the subsequent metabolic dysfunctions have been difficult to assess owing to its short half-life in vivo. Here, we demonstrate that a long-acting, pegylated analog of the NT peptide (P-NT) reduces food intake, body weight, and adiposity in diet-induced obese mice when administered once daily for 6 days. Strikingly, when P-NT was combined with the glucagon-like peptide 1 mimetic liraglutide, the two peptides syner-gized to reduce food intake and body weight relative to each monotherapy, without inducing a taste aversion. Further, P-NT and liraglutide coadministration improved glycemia and reduced steatohepatitis. Finally, we show that the melanocortin pathway is central for P-NT–induced anorexia and necessary for the full synergistic effect of P-NT and liraglutide combination therapy. Overall, our data suggest that P-NT and liraglutide combination therapy could be an enhanced treatment for obesity with improved tolerability compared with liraglutide monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85066455028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066455028&partnerID=8YFLogxK

U2 - 10.2337/db18-1009

DO - 10.2337/db18-1009

M3 - Article

VL - 68

SP - 1329

EP - 1340

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 6

ER -